Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, January 7, 2022
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
[ Fri, Jan 07th 2022
] - WOPRAI
Drew Ranieri Upgraded (TMCI) to Buy and Held Target at $30 on, Jan 7th, 2022
Drew Ranieri of Morgan Stanley, Upgraded "Treace Medical Concepts, Inc." (TMCI) to Buy and Held Target at $30 on, Jan 7th, 2022.
Drew has made no other calls on TMCI in the last 4 months.
There is 1 other peer that has a rating on TMCI. Out of the 1 peers that are also analyzing TMCI, 0 agree with Drew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Drew
- Danielle Antalffy of "SVB Leerink" Maintained at Buy with Decreased Target to $32 on, Friday, November 5th, 2021
